Source: Eur Respir J, 57 (4) 2100065; 10.1183/13993003.00065-2021
Disease area: Airway diseases, Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Valliappan Muthu, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Ritesh Agarwal. Is high-dose glucocorticoid beneficial in COVID-19?. Eur Respir J, 57 (4) 2100065; 10.1183/13993003.00065-2021

Member's Comments

No comment yet.

Related content which might interest you: Reply: Is high-dose glucocorticoid beneficial in COVID-19? Source: Eur Respir J, 57 (4) 2100324; 10.1183/13993003.00324-2021 Year: 2021 The efficacy of steroid with pentoxifylline in steroid resistant sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019 Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Does selenium long-term therapy restore hypothalamic-pituitary-adrenal axis in oral steroids dependant patients? Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009 Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004 Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Source: Eur Respir J 2011; 38: 947-958 Year: 2011 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001 Mechanisms of systemic side effects of inhaled steroids Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004 Muscle regrowth in COPD patients induced by anabolic steroids is amplified by systemic glucocorticoids (GC): A potentiating interaction between GC and IGF-1? Source: Annual Congress 2011 - Challenges in chronic disease management: helping individuals with chronic lung disease remain stable Year: 2011 Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020 Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids Source: Eur Respir J 2006; 27: 511-516 Year: 2006 Combination of pentoxifylline and steroids in sarcoidosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 269s Year: 2005 Low-dose inhaled glucocorticoids are more effective tham LTRA in improving functional data in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004 Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016